Insulet’s (NASDAQ:PODD) Q4: Beats On Revenue, Quarterly Revenue Guidance Slightly Exceeds Expectations
Insulin delivery company Insulet Corporation (NASDAQ:PODD) reported Q4 CY2024 results beating Wall Street’s revenue expectations, with sales up 17.2% year on year to $597.5 million. Guidance for next quarter’s revenue was better than expected at $545.5 million at the midpoint, 0.7% above analysts’ estimates. Its non-GAAP profit of $1.15 per share was 12.6% above analysts’ consensus estimates.